Loading...
Curaleaf Holdings, Inc.
CURA.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$5.22
CA$0.44(9.21%)

Over the last four quarters, Curaleaf Holdings, Inc.'s revenue moved from $337.42M in Q1 2024 to $331.05M in Q4 2024. Operating income in Q4 2024 was -$9.28M, with a strong operating margin of -3%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Curaleaf Holdings, Inc. remained robust at $26.07M, reflecting operational efficiency. Net income dropped to -$77.56M, with an EPS of $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan